Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Neck disc device study halted after just 2 patients

NCT ID NCT01433367

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at a disc replacement device called CerPass for people with a damaged disc in their neck. It aimed to see if the device could reduce pain and improve movement without needing further surgery. Only 2 people joined before the study was stopped early, so results are very limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2 people

The number who actually took part.

Start date

May 2010

Finished

Dec 2013

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Volunteers will be selected from the surgeon's existing clinic patients.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The criteria for inclusion into the proposed clinical study are as follows: 1. Age: 18-60 years of age (inclusive and skeletally mature); 2. A diagnosis of symptomatic cervical disc disease, defined as image-confirmed pathology: herniated disc, spondylosis, and/or loss of disc height. Spondylosis is defined as image-confirmed disc desiccation, loss of disc height, bridging osteophytes, and/or uncovertebral arthrosis. Loss of disc height is specified as a measurement of at least 25 degrees less than an adjacent nonsymptomatic level, but with a minimum of 1mm height remaining; 3. Functional neurological deficit (i.e., exhibits at least one sign associated with cervical level to be treated, including abnormal reflex, decreased motor strength, abnormal dermatome sensitivity, or pain in a dermatomal distribution); 4. Symptomatic level is C3-4, C4-5, C5-6 or C6-7 (one level); 5. Preoperative Neck Disability Index (NDI) greater than 30 points (considered moderate disability; Vernon 1991); 6. Unresponsive to conservative treatment for more than 6 weeks, and/or exhibits progressive symptoms and/or signs of nerve root and/or spinal cord compression in the face of conservative treatment; 7. Not pregnant, nor interested in becoming pregnant within the follow-up period of the study; 8. Willing and able to comply with the requirements defined in the protocol for the duration of the study; 9. Signed and dated Informed Consent. Exclusion Criteria: Patients with the following characteristics will not be eligible for entry into the proposed study: 1. Prior cervical fusion, prior laminectomy (prior cervical laminotomy that has not violated the facets need not be excluded), and/or prior cervical facetectomy at the operative level; 2. Requiring surgical treatment that would leave the patient with a postoperative deficiency of the posterior elements; 3. Signal changes in the cord on preoperative T2-weighted MRI and/or clinically significant myelopathy which would be described as gait disturbance, loss of manual dexterity, or bowel or bladder incontinence/retention. 4. Radiographic signs of significant instability at operative level (greater than 3mm translation, greater than 11 degree rotation different from adjacent level); 5. Bridging osteophytes or motion \< 3 degrees; 6. Radiographic confirmation of significant facet joint disease or degeneration; 7. Chronic neck or arm pain of unknown etiology; 8. Cervical fracture, anatomic anomaly, or deformity (e.g. ankylosing spondylitis, scoliosis) at the levels to which the prosthesis will be attached; 9. Severe spondylolisthesis (greater than grade 1); 10. Endocrine disorders or connective tissue diseases; 11. Rheumatoid arthritis or other autoimmune disease; 12. Progressive neuromuscular disease, e.g., muscular dystrophy, multiple sclerosis; 13. Chronic steroid users; 14. Taking any medications or drugs in doses that are known to potentially interfere with the bone metabolism or soft tissue healing, which may include (but is not limited to) the following: inhaled glucocorticoids for asthma, corticosteroids, thyroid hormones, blood thinners (heparin, warfarin), gonadotropin-releasing hormone agonists for prostate cancer treatment, contraceptive medroxyprogesterone, lithium for bi-polar disorder treatment, anticonvulsants, aluminum-containing antacids, tetracycline; 15. Osteoporosis to a degree that spinal instrumentation would be contraindicated (DEXA T-score less than or equal to -2.5; DEXA necessary only if patient exhibits risk factors for low bone mass as quantified in DEXA screening questionnaire); 16. Diabetes mellitus requiring insulin management; 17. Presence of metastases or active spinal tumor malignancy; 18. Body Mass Index (BMI) \> 40; 19. Active local or systemic infection, including AIDS, hepatitis; 20. Having been enrolled in another investigational device study within the last 90 days; 21. Having had another cervical device implanted that would interfere with the surgical approach, study or control device, or follow-up evaluations; 22. Demonstrates 3 or more signs of nonorganic behavior, such as Waddell's signs; 23. History of substance abuse; 24. Involved in spinal litigation; 25. Mentally incompetent; 26. Incarcerated.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical disc disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Del Prado

    Tijuana, Estado de Baja California, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.